<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335350">
  <stage>Registered</stage>
  <submitdate>8/04/2010</submitdate>
  <approvaldate>9/04/2010</approvaldate>
  <actrnumber>ACTRN12610000289011</actrnumber>
  <trial_identification>
    <studytitle>Does Caralluma fimbriata extract (Slimaluma) reduce the risk factors of metabolic syndrome  in overweight and obese adults?</studytitle>
    <scientifictitle>The effects of Caralluma fimbriata extract (Slimaluma) in combination with lifestyle intervention on the risk factors of metabolic syndrome  in overweight and obese adults: a randomised controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prevention of metabolic syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Caralluma fimbriata extract capsule 500mg oral administration, twice per day 
before meals for three months.
Water soluble, Caralluma fimbriata extract containing 27.8% Pregnane Glycosides and 13.3% Saponin Glvcosides.  Lifestyle intervention focuses on healthy dietary intake based on the Dietary guidelines for Australian adults for three months.</interventions>
    <comparator>Placebo capsule containing maltodextrin, 500mg oral administration, twice per day before meals for three months.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood analysis in circulating levels of  leptin, glucose, triglyceride, total cholesterol and high density lipoprotein (HDL).</outcome>
      <timepoint>pre- and post-intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anthropometric measurements including body weight and waist circumference.</outcome>
      <timepoint>pre- and post-intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Basal metobolic rate (BMR) will be measured using the metabolic cart (closed circuit spirometry).</outcome>
      <timepoint>pre- and post-intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood analysis of adiponectin,  Glucagon-like peptide-1 (GLP1), C-reactive protein (CRP) and homocystiene.</outcome>
      <timepoint>pre- and post-intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Males and females aged 30-60 years with a body mass index (BMI) greater than 25 or a waist circumference &gt; 94cm for males and &gt;80cm for females.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Liver, kidney and heart disease, pregnancy, type 1 and type 2 diabetes with insulin medication, cigarette smoking and the use of any medication for weight loss.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3029</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Victoria University</primarysponsorname>
    <primarysponsoraddress>McKechnie Street
St Albans,
PO BOX 14428
Melbourne, Victoria 8001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Victoria University</fundingname>
      <fundingaddress>McKechnie Street
St Albans,
PO BOX 14428
Melbourne, Victoria 8001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A 3-month intervention using encapsulated Caralluma fimbriata extract in combination with lifestyle intervention to investigate whether or not Caralluma fimbriata extract  suppresses the appetite and decreases the risk factors of metabolic syndrome</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Victoira University Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Victoria University
PO Box 14428
Melbourne VIC 8001</ethicaddress>
      <ethicapprovaldate>23/03/2010</ethicapprovaldate>
      <hrec>HRETH10/22</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Xiao Su &amp; Michael Mathai</name>
      <address>School of Biomedical &amp; Health Sciences
Victoria University
McKechnie Street
St Albans
PO Box 14428,
Melbourne VIC 8001</address>
      <phone>+61 3 9919 2318; +61 3 9919 2211</phone>
      <fax>+61 3 9919 2465</fax>
      <email>xiao.su@vu.edu.au; Michael.Mathai@vu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Katie Astell</name>
      <address>School of Biomedical &amp; Health Sciences
Victoria University
McKechnie Street
St Albans
PO Box 14428,
Melbourne VIC 8001</address>
      <phone>+61 413 974 652</phone>
      <fax>+61 3 9919 2465</fax>
      <email>katie.astell@live.vu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Xiao Su &amp; Michael Mathai</name>
      <address>School of Biomedical &amp; Health Sciences
Victoria University
McKechnie Street
St Albans
PO Box 14428,
Melbourne VIC 8001</address>
      <phone>+61 3 9919 2318; +61 3 9919 2211</phone>
      <fax>+61 3 9919 2465</fax>
      <email>xiao.su@vu.edu.au; Michael.Mathai@vu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>